Evidence map›Paper›PMID 27832104›Full record

ArticlePloS one2016

Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.

Katerina Melachroinou, Emmanouela Leandrou, Polytimi-Eleni Valkimadi, Anna Memou, Georgios Hadjigeorgiou, Leonidas Stefanis, Hardy J Rideout

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  7. Article
  8. Article
  9. Allosteric inhibition of LRRK2, where are we now.Biochemical Society transactions · 2020
    Review
  10. Review
  11. Review
  12. Review
  13. Vitamin BCell research · 2019
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Katerina MelachroinouDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Emmanouela LeandrouDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Polytimi-Eleni ValkimadiDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Anna MemouDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Georgios HadjigeorgiouDepartment of Neurogenetics, Institute of Biomedical Research & Technology (CERETETH), Larissa, Greece.
Leonidas StefanisDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Hardy J RideoutDivision of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Biomedical Research Foundation of the Academy of Athens · GRNational and Kapodistrian University of Athens · GRUniversity of Thessaly · GR

Funding

Parkinson's UK K-1208
6 · The paper itself

Abstract

backgroundDespite the plethora of sequence variants in LRRK2, only a few clearly segregate with PD. Even within this group of pathogenic mutations, the phenotypic profile can differ widely.

objectiveWe examined multiple properties of LRRK2 behavior in cellular models over-expressing three sequence variants described in Greek PD patients in comparison to several known pathogenic and non-pathogenic LRRK2 mutations, to determine if specific phenotypes associated with pathogenic LRRK2 can be observed in other less-common sequence variants for which pathogenicity is unclear based on clinical and/or genetic data alone.

methodsThe oligomerization, activity, phosphorylation, and interaction with FADD was assessed in HEK293T cells over-expressing LRRK2; while the induction of neuronal death was determined by quantifying apoptotic nuclei in primary neurons transiently expressing LRRK2.

resultsOne LRRK2 variant, A211V, exhibited a modest increase in kinase activity, whereas only the pathogenic mutants G2019S and I2020T displayed significantly altered auto-phosphorylation. We observed an induction of detergent-insoluble high molecular weight structures upon expression of pathogenic LRRK2 mutants, but not the other LRRK2 variants. In contrast, each of the variants tested induced apoptotic death of cultured neurons similar to pathogenic LRRK2 in a FADD-dependent manner.

conclusionsOverall, despite differences in some properties of LRRK2 function such as kinase activity and its oligomerization, each of the LRRK2 variants examined induced neuronal death to a similar extent. Furthermore, our findings further strengthen the notion of a convergence on the extrinsic cell death pathway common to mutations in LRRK2 that are capable of inducing neuronal death.

Indexed as

MutationSignal TransductionCell DeathCell LineCells, CulturedFas-Associated Death Domain ProteinGuanosine TriphosphateHEK293 CellsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2NeuronsParkinson DiseasePhosphorylationProtein Interaction MapsFADD protein, humanFas-Associated Death Domain ProteinGuanosine TriphosphateLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Identifiers

PMID27832104
PMCPMC5104429
OpenAlexW2549434099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.